Vivoryon Therapeutics N.V. | Small-cap | Healthcare
€1.65
-1.20%
| Vivoryon Stock Comparison:
Vivoryon vs Galapagos NVVivoryon vs Pharming Group N.VVivoryon vs Koninklijke PhilipsVivoryon vs Renewi PlcVivoryon vs London Tunnels PLCVivoryon vs AEX Index | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 6.4M
Total Liabilities 3.2M
Shareholders Equity 3.2M
Debt to Equity 1.02

Cash Flow Metrics

Revenue & Profitability Trend

Vivoryon Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i0-3.6M010.8M0
Cost of Goods Sold i0-525.0K01.6M0
Gross Profit i0-3.1M09.2M0
Gross Margin % i0.0%0.0%0.0%85.4%0.0%
Operating Expenses
Research & Development i14.1M17.6M20.2M17.5M13.2M
Selling, General & Administrative i3.5M3.3M4.9M2.4M1.5M
Other Operating Expenses i3.0K-42.0K-54.0K100.0K-
Total Operating Expenses i17.6M20.9M25.1M19.9M14.7M
Operating Income i-21.0M-28.8M-29.1M-12.9M-16.0M
Operating Margin % i0.0%0.0%0.0%-119.8%0.0%
Non-Operating Items
Interest Income i426.0K478.0K42.0K21.0K26.0K
Interest Expense i47.0K56.0K24.0K24.0K23.0K
Other Non-Operating Income-----
Pre-tax Income i-20.6M-28.6M-28.4M-12.2M-16.5M
Income Tax i0-234.0K-199.0K432.0K0
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-20.6M-28.3M-28.2M-12.7M-16.5M
Net Margin % i0.0%0.0%0.0%-117.6%0.0%
Key Metrics
EBITDA i-20.4M-28.4M-28.2M-12.0M-16.3M
EPS (Basic) i€-0.79€-1.12€-1.28€-0.63€-0.83
EPS (Diluted) i€-0.79€-1.12€-1.28€-0.63€-0.83
Basic Shares Outstanding i2606680925242140220195572000001419975482
Diluted Shares Outstanding i2606680925242140220195572000001419975482

Income Statement Trend

Vivoryon Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i9.4M18.6M26.6M14.7M26.3M
Short-term Investments i21.0K10.0M7.0K7.0K21.0K
Accounts Receivable i-----
Inventory i-----
Other Current Assets639.0K495.0K-1.9M-
Total Current Assets i10.1M29.8M30.7M20.2M28.8M
Non-Current Assets
Property, Plant & Equipment i142.0K159.0K157.0K150.0K465.0K
Goodwill i865.0K941.0K494.0K533.0K565.0K
Intangible Assets i865.0K941.0K494.0K533.0K565.0K
Long-term Investments-----
Other Non-Current Assets228.0K----
Total Non-Current Assets i1.2M1.0M684.0K4.3M958.0K
Total Assets i11.3M30.8M31.4M24.5M29.8M
Liabilities
Current Liabilities
Accounts Payable i1.0M2.9M2.5M4.4M911.0K
Short-term Debt i60.0K38.0K94.0K92.0K90.0K
Current Portion of Long-term Debt-----
Other Current Liabilities324.0K1.0K6.0K3.0K1.0K
Total Current Liabilities i1.4M3.2M3.3M5.1M1.3M
Non-Current Liabilities
Long-term Debt i42.0K038.0K132.0K224.0K
Deferred Tax Liabilities i-0234.0K432.0K0
Other Non-Current Liabilities-1.0K--513.0K-
Total Non-Current Liabilities i2.0M1.4M1.6M2.9M2.2M
Total Liabilities i3.4M4.5M4.9M8.0M3.5M
Equity
Common Stock i261.0K26.1M24.1M20.0M20.0M
Retained Earnings i-169.4M-148.8M-120.5M-92.3M-79.6M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i7.9M26.3M26.5M16.6M26.2M
Key Metrics
Total Debt i102.0K38.0K132.0K224.0K314.0K
Working Capital i8.7M26.6M27.4M15.2M27.5M

Balance Sheet Composition

Vivoryon Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-20.6M-28.3M-28.2M-12.7M-16.5M
Depreciation & Amortization i-----
Stock-Based Compensation i2.2M3.9M3.5M1.8M159.0K
Working Capital Changes i294.0K-679.0K2.9M-3.9M1.4M
Operating Cash Flow i-18.5M-22.4M-19.1M-15.0M-14.5M
Investing Activities
Capital Expenditures i-2.0K-14.0K-11.0K-20.0K-64.0K
Acquisitions i-----
Investment Purchases i0-19.0M0--
Investment Sales i10.0M9.0M0--
Investing Cash Flow i10.0M-10.0M-11.0K-20.0K-64.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i024.3M34.2M1.1M0
Free Cash Flow i-19.2M-22.1M-21.8M-11.3M-14.7M
Net Change in Cash i-8.5M-8.2M15.1M-13.8M-14.6M

Cash Flow Trend

Vivoryon Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -2.07
Forward P/E -2.24
Price to Book 13.87
PEG Ratio -2.24

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -145.47%
Return on Assets -67.68%

Financial Health

Current Ratio 4.04
Debt to Equity 2.26
Beta 1.96

Per Share Data

EPS (TTM) €-0.48
Book Value per Share €0.12
Revenue per Share €0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
vvy43.5M-2.0713.87-145.47%0.00%2.26
Galapagos NV 1.9B51.710.72-10.39%-103.14%0.32
Pharming Group N.V 841.3M57.153.45-3.70%-2.41%53.57
Koninklijke Philips 22.7B150.002.201.51%0.91%80.96
Renewi Plc 830.4M27.112.729.61%-3.45%201.48
London Tunnels PLC 123.1M-1,285.7113.97-83.27%0.00%38.01

Financial data is updated regularly. All figures are in the company's reporting currency.